ICYMI – May 15, 2015 ***** The New England Journal of Medicine: “The $2.6 Billion Pill — Methodologic and Policy Considerations” “Of course, it is extremely expensive and risky to develop a new medication…but as risky as drug development is, the pharmaceutical and biotech industries remain among the most profitable sectors of the U.S. economy and actually […]
May 14, 2015 The House Energy and Commerce Committee released an updated draft of the 21st Century Cures bill last night in a last minute effort to address concerns over drug exclusivity, interoperability and tele health before today’s markup. However, many organizations are still concerned about Congress’ lack of legislation to address high drug costs. Pew Charitable Trusts […]
May 13, 2015 New Drug Report Reveals Drug Costs Top $50,000/year for Over Half a Million Americans Reaction from National Coalition on Health Care President and CEO John Rother on key findings from Express Scripts “Super Spending: U.S. Trends in High-Cost Medication Use.” “The Express Scripts “Super Spending: U.S. Trends in High-Cost Medication Use” report released today […]
ICYMI May 5, 2015 The New York Times: Runaway Drug Prices How companies set prices of specialty drugs for these and other complex diseases, like cancer and AIDS, has been a mystery to the patients who need them.” “The drug and biotech companies contend that high prices are justified to cover the large costs of bringing […]
April 28, 2015 Note: Distributing the New York Times article below is not an endorsement for President Obama’s proposed initiative. New York Times: Obama Proposes That Medicare Be Given the Right to Negotiate the Cost of Drugs “Five years after passage of the Affordable Care Act, drug prices are emerging again as a political issue. On a […]
This morning, the National Journal published an article regarding an increase in public concern over the high cost of prescription drugs. The article references CSRxP’s white paper, “Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System.”
Reaction from National Coalition on Health Care President and CEO John Rother on key findings from the “Express Scripts 2014 Drug Trend Report.”
A national group of more than 140,000 physicians on Tuesday joined a coalition dedicated to reversing the growing trend of high-cost specialty drugs, which are being blamed for straining the finances of patients, insurance plans and public health coverage programs.
The cost to develop a new drug and win FDA marketing approval is now pegged at nearly $2.6 billion, according to a new report from the Tufts Center for the Study of Drug Development.
With the California-based drug manufacturer Gilead Sciences planning to roll out another hepatitis C medication, academics said Wednesday that policy changes are needed in the costly drug market so the interests of patients, health insurers and pharmaceutical companies align.